Bayer AG is in talks to buy Vividion Therapeutics in a roughly $2 billion deal, enforcing new IPO plans for Vividion.
Sanofi’s CEO Paul Hudson is dead serious about mRNA technology and capabilities with a $3.2 billion acquisition offer to Translate Bio.
Bristol-Myers Squibb, the Big Pharma company, has entered into a drug discovery collaboration worth $1.2 billion, with artificial intelligence (AI) pharmatech company, Exscientia.
German pharma giant Bayer has plans to introduce three news drugs with annual sales potential of $1.22 billion (€1 billion) but these will not offset the fall in revenue the comp
French healthcare company Sanofi has agreed to acquire U.S. company Principia Biopharma Inc. for around $3.7 billion.